Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ004309 + atezolizumab
- Development stage
- Unknown
- Lead developer
- TRACON Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TJ004309 + atezolizumab is a combination investigational regimen of **uliledlimab (TJ004309)**, a novel, humanized monoclonal antibody targeting CD73, and **atezolizumab (Tecentriq)**, a PD-L1 checkpoint inhibitor monoclonal antibody. Uliledlimab inhibits the CD73-mediated conversion of AMP to adenosine, thereby reducing immunosuppression in the tumor microenvironment. Atezolizumab blocks the interaction of PD-L1 with PD-1 and B7.1, enhancing T-cell function and anti-tumor immunity. This combination is being developed for the treatment of advanced or metastatic solid tumors, with particular focus on patients who are refractory to or intolerant of standard therapies. The development is primarily led by TRACON Pharmaceuticals and I-Mab Biopharma[4][6].
- Brand names
- Tecentriq
- Other names
- TJ004309 + Tecentriquliledlimab + atezolizumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on TJ004309 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ004309 + atezolizumab.